Search
PDS Biotechnology Corp
PDSBAdd to Watchlist
1.020USD
-0.045-4.23%
Close 10-08 16:00（ET）
57.04MMarket Cap
LossP/E TTM
After-hours 18:49 (ET)1.020USD-0.020-1.92%
After-hours 18:49 (ET)PDS Biotechnology Corp (PDSB) Stock Price Target & Forecast
Analyst Rating
Based on 3 analysts giving stock ratings to PDS Biotechnology Corp in the past month.
Buy
0 Strong Buy
3 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
4.167USD+456.67%
PDSB Analyst Recommendation Trends
In the current month, PDSB has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PDSB average Analyst price target in the last month is 4.167.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
PDSB Analyst Rating for Peer Comparison
Updated: Oct 8, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
18
0
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
14
1
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
11
3
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Financial Forecasting
Based on analysts' estimates, PDSB EPS is projected to reach -0.105 in FY2026Q3, following reported EPS of -0.175 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.19
-0.15
-0.13
-0.10
-0.09
Actual
-0.15
-0.13
-0.18
--
--
Surprise
+22.85%
+11.72%
-34.75%
--
--
FAQs
What is PDS Biotechnology Corp's price target?
Analysts forecast that PDS Biotechnology Corp's price target is USD 4.17, with the highest forecast at USD 5.00 and the lowest forecast at USD 3.00.
How have PDS Biotechnology CorpPDSB's recent earnings per share performed?
The market expectation was USD -0.18, while PDS Biotechnology CorpPDSB's earnings per share (EPS) for the previous quarter was USD -0.13. EPS for the next quarter is expected at USD -0.10.
What is the analyst rating for PDS Biotechnology Corp?
Based on the ratings of PDS Biotechnology Corp's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.